National TB Elimination Program (NTEP) – Evidence‑Based Treatment Guidelines for Tuberculosis in India
1. Drug‑Susceptible Tuberculosis
1.1 Standard adult regimen
- The recommended regimen for drug‑susceptible pulmonary TB in adults is a 6‑month course: 2 months of isoniazid, rifampin, pyrazinamide and ethambutol followed by 4 months of isoniazid + rifampin (2HRZE/4HR) 1.
1.2 Dosing schedule
- Daily drug administration is strongly preferred to intermittent dosing, with directly observed therapy (DOT) provided 5–7 days per week 2.
1.3 Weight‑based dosing for a ~70 kg adult (rounded to nearest practical tablet)
| Drug | Daily dose (approx.) |
|---|---|
| Isoniazid | 300 mg (≈5 mg/kg, max 300 mg) |
| Rifampin | 600 mg (≈10 mg/kg, max 600 mg) |
| Pyrazinamide | 2 g (15–30 mg/kg, capped at 2 g) |
| Ethambutol | 1.2 g (15–25 mg/kg for 56–75 kg weight band) |
| Pyridoxine (vit B6) | 25–50 mg daily with isoniazid to prevent peripheral neuropathy |
*These doses are derived from the NTEP weight‑band recommendations 1.
1.4 Pediatric regimen (3 months – 16 years)
- For children with non‑severe TB (no cavitation, no suspicion of MDR/RR‑TB), a 4‑month regimen (2HRZ(E)/2HR) is recommended instead of the traditional 6‑month course 2.
1.5 Baseline and ongoing monitoring
- Baseline tests before treatment: visual acuity (Snellen), colour discrimination (Ishihara), liver function (AST, ALT, bilirubin, alkaline phosphatase), serum creatinine, and platelet count 1.
- Monthly follow‑up: ask patients about visual disturbances while they are receiving ethambutol 1.
2. Drug‑Resistant Tuberculosis
2.1 Diagnostic prerequisite
- Molecular testing for fluoroquinolone resistance (e.g., Xpert MTB/XDR) must be performed before initiating any shorter regimen 3.
2.2 Rifampin‑resistant, fluoroquinolone‑susceptible TB (MDR/RR‑TB) – adolescents ≥ 14 yr and adults
- Use the 6‑month all‑oral BPaLM regimen (bedaquiline + pretomanid + linezolid + moxifloxacin) 2.
2.2.1 BPaLM dosing (26 weeks)
| Drug | Dose & schedule |
|---|---|
| Bedaquiline | 400 mg daily × 2 weeks, then 200 mg three times weekly for the remaining 24 weeks |
| Pretomanid | 200 mg daily |
| Linezolid | 600 mg daily |
| Moxifloxacin | 400 mg daily |
*All drugs are taken with food; avoid milk or antacids. DOT is provided 5 days per week 2.
2.3 Rifampin‑resistant TB with fluoroquinolone resistance or intolerance
- Use the 6‑month BPaL regimen (bedaquiline + pretomanid + linezolid, without moxifloxacin). Reported treatment success is 90–100 % 2.
2.4 Longer MDR‑TB regimens (when BPaL/BPaLM unsuitable)
- Backbone: All three Group A agents—levofloxacin/moxifloxacin, bedaquiline, and linezolid—should be included, together with at least one Group B agent, to ensure ≥ 4 effective drugs at treatment start 3.
- Strengthened recommendations: Bedaquiline and linezolid are now strongly recommended (upgraded from conditional) for longer MDR‑TB regimens in adults ≥ 18 years 3.
- Injectables excluded: Kanamycin and capreomycin must not be used in MDR/RR‑TB treatment 3.
2.5 Isoniazid‑resistant, rifampin‑susceptible TB
- Recommended 6‑month regimen: rifampin, ethambutol, pyrazinamide, and levofloxacin 3.
- Injectable agents such as streptomycin should not be added 3.
3. Special Situations
3.1 Tuberculous pericarditis
- Treat with the standard 6‑month four‑drug regimen (HRZE) because pericardial TB is a severe manifestation 4.
- Adjunctive corticosteroids: Prednisone 1–2 mg/kg/day for 5–7 days, then taper over 6–8 weeks 4.
- Procedural interventions:
- Empiric therapy in endemic areas: In TB‑endemic regions like India, empiric anti‑TB chemotherapy is recommended for exudative pericardial effusions after other causes have been excluded 4.
Standard Treatment and Management of Drug‑Susceptible Tuberculosis
Recommended Regimen
- For adults with drug‑susceptible pulmonary tuberculosis, a 6‑month regimen is advised: 2 months of isoniazid + rifampin + pyrazinamide + ethambutol (2HRZE) followed by 4 months of isoniazid + rifampin (4HR) 5.
Dosing Frequency and Directly Observed Therapy
- Daily administration of all four first‑line drugs is strongly preferred over intermittent schedules, with directly observed therapy (DOT) provided 5–7 days per week 5.
- If intermittent dosing must be used during the continuation phase, a thrice‑weekly schedule is preferred to a twice‑weekly schedule 5.
- Once‑weekly therapy that combines isoniazid 900 mg with rifapentine 600 mg in the continuation phase is not recommended because it yields inferior treatment outcomes 5.
Inclusion of Ethambutol in the Initial Regimen
- Ethambutol (or streptomycin for young children unable to undergo visual‑acuity monitoring) should be included in the initial regimen until drug‑susceptibility results are available, unless the community prevalence of primary isoniazid resistance is < 4 % and the patient has no prior anti‑tuberculosis treatment, no recent travel from a high‑resistance country, and no known exposure to a drug‑resistant case 5.
Management of Treatment Interruptions
| Phase | Interruption Length | Action |
|---|---|---|
| Intensive (first 2 months) | < 14 days | Continue treatment, ensuring the total planned number of doses is completed within 3 months [5]. |
| Intensive (first 2 months) | ≥ 14 days | Restart the entire regimen from the beginning [5]. |
| Continuation (months 3–6) – patient received ≥ 80 % of doses & initial sputum smear‑negative | – | Continue therapy until all scheduled doses are taken [5]. |
| Continuation – patient received ≥ 80 % of doses & initial sputum smear‑positive | – | Continue therapy until all scheduled doses are taken unless a consecutive lapse exceeds 2 months [5]. |
| Continuation – patient received < 80 % of doses & cumulative lapse < 3 months | – | Restart the regimen only if the remaining treatment cannot be completed within the recommended timeframe [5]. |
| Continuation – patient received < 80 % of doses & lapse ≥ 3 months | – | Restart the regimen from the beginning, instituting new intensive and continuation phases [5]. |
- For patients who were lost to follow‑up and later re‑engaged, repeat sputum collection for acid‑fast bacilli smear, culture, and drug‑susceptibility testing 5.
Adverse‑Effect Management
- Mild adverse effects are usually managed with symptomatic treatment; severe adverse effects generally require discontinuation of the offending drug(s) and may necessitate expert consultation 5.
- When a drug is permanently discontinued, a replacement drug from a different pharmacologic class should be added to the regimen 5.
- In cases of severe tuberculosis where a drug must be held, an alternate regimen should be initiated during the interruption 5.
- Complex diagnostic or therapeutic situations should prompt consultation with local and state health departments 5.
Shortened 4‑Month Anti‑Tubercular Regimen for Non‑Severe Tuberculosis in Infants
Guideline Recommendation
- The 2025 American Thoracic Society / CDC / European Respiratory Society / Infectious Diseases Society of America (ATS/CDC/ERS/IDSA) guidelines strongly recommend a 4‑month regimen (2 HRZ(E)/2 HR) for children aged 3 months to 16 years with non‑severe, drug‑susceptible tuberculosis, replacing the traditional 6‑month course. This is a strong recommendation with moderate certainty of evidence. [6][7]
Definition of Non‑Severe Disease
- Non‑severe tuberculosis is defined as disease without cavitation, without extensive pulmonary involvement, and without suspicion of multidrug‑resistant or rifampin‑resistant TB. [6][7]
Regimen Composition for Infants (3–12 months)
- Intensive phase (first 2 months): isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) (or streptomycin in infants who cannot undergo visual monitoring). [6][7]
- Continuation phase (next 2 months): isoniazid (H) and rifampin (R). [6][7]
Alternative Fourth Drug When Visual Monitoring Is Not Feasible
- In infants who cannot reliably report visual symptoms, streptomycin (or ethionamide) may be substituted for ethambutol as the fourth drug in the intensive phase. [6][7]
MDR‑TB Regimen for Older Children and Adolescents
- For adolescents ≥ 14 years with rifampin‑resistant, fluoroquinolone‑susceptible TB, the 2025 ATS/CDC/ERS/IDSA guidelines recommend a 6‑month BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin). [6][7]